Semaxanib, also known as SU5416, is a tyrosine kinase inhibitor primarily researched for its potential in treating colorectal and lung cancers by inhibiting angiogenesis. As a small molecule therapeutic,… Read more
Semaxanib, also known as SU5416, is a tyrosine kinase inhibitor primarily researched for its potential in treating colorectal and lung cancers by inhibiting angiogenesis. As a small molecule therapeutic, its development and rigorous analytical evaluation require high-quality reference materials to ensure safety and efficacy. This category provides access to Semaxanib reference standards, including related substances and stereoisomers such as Semaxinib, alongside essential metabolites and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for impurity profiling, method development, and validation of analytical procedures like HPLC or LC-MS. By incorporating accurate internal standards, including deuterated or isotopically labelled analogs, researchers can achieve greater precision in quantitative analysis. These reference materials support comprehensive quality control protocols throughout the drug development lifecycle, ensuring compliance with regulatory standards for purity and structural characterization.